Century Therapeutics (IPSC) Other Non Operating Income (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Other Non Operating Income of $20000.0 for Q1 2026, up 152.63% year-over-year from $7916.7 in Q1 2025, and up 111.05% quarter-over-quarter from -$181000.0 in Q4 2025.
Century Therapeutics (IPSC) Other Non Operating Income (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Other Non Operating Income for 7 consecutive years, with $20000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 152.63% year-over-year to $20000.0; the TTM figure through Mar 2026 stood at $49000.0 (up 120.85% YoY), while the FY2025 annual figure was -$9000.0, up 95.19% from the prior year.
- Other Non Operating Income advanced to $20000.0 in Q1 2026 per IPSC's latest filing, from -$181000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $4.4 million in Q4 2022 and bottomed at -$435000.0 in Q4 2024.
- Historically, Other Non Operating Income has averaged $223588.2 across 5 years, with a median of -$12000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Non Operating Income soared 2593.82% — and 2023, when it slumped 3820.0%.
- Century Therapeutics' Other Non Operating Income stood at $4.4 million in 2022, then slumped by 100.34% to -$15000.0 in 2023, then sank by 2800.0% to -$435000.0 in 2024, then surged by 58.39% to -$181000.0 in 2025, then jumped by 111.05% to $20000.0 in 2026.
- Business Quant data shows IPSC's Other Non Operating Income at $20000.0 in Q1 2026, -$181000.0 in Q4 2025, and $97000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | -181,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Dec 31, 2024 | -435,000.00 |
| Sep 30, 2024 | 250,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | -15,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | -186,000.00 |
| Mar 31, 2023 | -194,000.00 |
| Dec 31, 2022 | 4.44 Mn |
| Sep 30, 2022 | -24,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | -61,000.00 |
| Dec 31, 2021 | -178,000.00 |
| Sep 30, 2021 | 140,000.00 |